STEVEN I SHERMAN to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Diabetes Mellitus, Type 2.
Connection Strength
0.159
-
No Evidence of Increase in Calcitonin Concentrations or Development of C-Cell Malignancy in Response to Liraglutide for Up to 5 Years in the LEADER Trial. Diabetes Care. 2018 03; 41(3):620-622.
Score: 0.072
-
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab. 2011 Jul; 96(7):2027-31.
Score: 0.046
-
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010 Feb; 33(2):428-33.
Score: 0.042